Eli Lil­ly flesh­es out more PhI­II da­ta for Dupix­ent chal­lenger as AD ri­val­ry heats up

Eli Lil­ly out­lined more da­ta for its IL-13 in­hibitor Mon­day as it pre­pares to chal­lenge the megablock­buster Dupix­ent in atopic der­mati­tis.

Lil­ly’s le­brik­izum­ab cleared up pa­tients’ skin at a sta­tis­ti­cal­ly sig­nif­i­cant­ly greater rate com­pared to place­bo in two dif­fer­ent mea­sure­ments, the phar­ma said Mon­day morn­ing, flesh­ing out the piv­otal tri­al da­ta pack­age ahead of an even­tu­al NDA sub­mis­sion. Mon­day’s read­out was le­brik­izum­ab’s third Phase III study to read out pos­i­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER